HER2/neu-directed therapy for biliary tract cancer

被引：0

作者：

Milind Javle

Chaitanya Churi

HyunSeon C. Kang

Rachna Shroff

Filip Janku

Rakesh Surapaneni

Mingxin Zuo

Christian Barrera

Humaid Alshamsi

Sunil Krishnan

Lopa Mishra

Robert A. Wolff

Ahmed O. Kaseb

Melanie B. Thomas

Abby B. Siegel

机构：

[1] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

[2] The University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology, Division of Diagnostic Imaging

[3] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics, Division of Cancer Medicine

[4] Scott & White Clinic,Department of Radiation Oncology, Division of Radiation Oncology

[5] The University of Texas MD Anderson Cancer Center,Department of Gastroenterology

[6] The University of Texas MD Anderson Cancer Center,Departments of Medicine and Surgery

[7] Gibbs Cancer Center & Research Institute,undefined

[8] Columbia University,undefined

来源：

Journal of Hematology & Oncology | / 8卷

关键词：

Receptor; ErbB-2; Gallbladder neoplasms; Cancer of the biliary tract;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[11] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
Harbeck, Nadia
Pegram, Mark D.
Rueschoff, Josef
Moebus, Volker
BREAST CARE, 2010, 5 : 3 - 7
[12] Value of Serum Human Epidermal Growth Factor Receptor 2 (HER2)/neu Testing for Early Prediction of Response to HER2/neu-Directed Therapies Is Still an Open One and Deserves Further Study in Large Prospective Trials
Ali, Suhail M.
Leitzel, Kim
Lipton, Allan
Carney, Walter P.
Koestler, Wolfgang J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : e273 - e273
[13] HER2/neu vaccines in breast cancer
Khoo, Steven
Ponniah, Sathibalan
Peoples, George E.
WOMENS HEALTH, 2006, 2 (02) : 217 - 223
[14] Value of Serum Human Epidermal Growth Factor Receptor 2 (HER2)/neu Testing for Early Prediction of Response to HER2/neu-Directed Therapies Is Still an Open One and Deserves Further Study in Large Prospective Trials Reply
Lennon, Sian
Barton, Claire
Banken, Ludger
Gianni, Luca
Marty, Michel
Baselga, Jose
Leyland-Jones, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : e274 - e275
[15] The Role of HER2 Status in the Biliary Tract Cancers
Ayasun, Ruveyda
Ozer, Muhammet
Sahin, Ilyas
CANCERS, 2023, 15 (09)
[16] HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer
Vivaldi, Caterina
Fornaro, Lorenzo
Ugolini, Clara
Niccoli, Cristina
Musettini, Gianna
Pecora, Irene
Cacciato Insilla, Andrea
Salani, Francesca
Pasquini, Giulia
Catanese, Silvia
Lencioni, Monica
Masi, Gianluca
Campani, Daniela
Fontantini, Gabriella
Falcone, Alfredo
Vasile, Enrico
ONCOLOGIST, 2020, 25 (10): : 886 - 893
[17] Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Ricci, Angela Dalia
Rizzo, Alessandro
MEDICINA-LITHUANIA, 2021, 57 (12):
[18] HER2/neu in systemic therapy for women with breast cancer:: a systematic review
Dhesy-Thind, Bindi
Pritchard, Kathleen I.
Messersmith, Hans
O'Malley, Frances
Elavathil, Leela
Trudeau, Maureen
BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 209 - 229
[19] HER2/neu in systemic therapy for women with breast cancer: a systematic review
Bindi Dhesy-Thind
Kathleen I. Pritchard
Hans Messersmith
Frances O’Malley
Leela Elavathil
Maureen Trudeau
Breast Cancer Research and Treatment, 2008, 109 : 209 - 229
[20] Targeting the product of the HER2/neu protooncogene for therapy
Carter, P
BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 139 - 146

← 1 2 3 4 5 →